Sol-Gel Technologies Ltd. announced on April 17, 2025, a product purchase agreement with a subsidiary of Mayne Pharma Group Limited for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO. The agreement is valued at a total of $16 million.
Under the terms, Sol-Gel will receive $10 million in the second quarter of 2025 and an additional $6 million in the fourth quarter of 2025. This transaction is expected to extend the company's cash runway into the first quarter of 2027, providing critical funding for its operations.
This strategic move allows Sol-Gel to concentrate on the clinical and commercial development of its most advanced innovative product, SGT-610, a hedgehog signaling pathway blocker for Gorlin syndrome. The company estimates the U.S. market potential for SGT-610 to be between $400 million and $500 million annually.
The Phase 3 clinical trial for SGT-610 is progressing, with approximately 80% of the planned patients enrolled across 41 sites. Top-line results for SGT-610 are anticipated in the fourth quarter of 2026, representing a key future catalyst. Additionally, Sol-Gel expects to file for a Phase 2 IND for SGT-210 in Q2 2025, targeting rare hyperkeratinization disorders with an estimated market potential of $200 million to $300 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.